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The plant virus, cowpea mosaic virus (CPMV), is increasingly being used as a nanoparticle platform for multivalent display of peptides. A
growing variety of applications have employed the CPMV display technology including vaccines, antiviral therapeutics, nanoblock chemistry, and
materials science. CPMV chimeras can be inexpensively produced from experimentally infected cowpea plants and are completely stable at 37 -C
and low pH, suggesting that they could be used as edible or mucosally-delivered vaccines or therapeutics. However, the fate of CPMV particles in
vivo, or following delivery via the oral route, is unknown. To address this question, we examined CPMV in vitro and in vivo. CPMV was shown
to be stable under simulated gastric conditions in vitro. The pattern of localization of CPMV particles to mouse tissues following oral or
intravenous dosing was then determined. For several days following oral or intravenous inoculation, CPMV was found in a wide variety of tissues
throughout the body, including the spleen, kidney, liver, lung, stomach, small intestine, lymph nodes, brain, and bone marrow. CPMV particles
were detected after cardiac perfusion, suggesting that the particles entered the tissues. This pattern was confirmed using methods to specifically
detect the viral capsid proteins and the internal viral RNA. The stability of CPMV virions in the gastrointestinal tract followed by their systemic
dissemination supports their use as orally bioavailable nanoparticles.
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Development of orally bioavailable delivery systems for
vaccines and therapeutics is an important pharmacologic
challenge. Awide variety of micro- and nanoparticulate carriers
are currently being studied for delivery to tissues in the body
via oral or mucosal inoculation. These include biodegradable0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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and Baird, 2001), liposomes and lipid-based systems (Hussain
et al., 2001), latex and polystyrene beads, polyalkyl-cyanoac-
rylate nanocapsules (Damge et al., 1990, 1997), nanoparticles
made up of fatty acid polymers (Mathiowitz et al., 1997), and
titanium dioxide particles (Jani et al., 1994). Each of these
delivery systems has advantages and disadvantages for their
use as mucosally administered carriers, including variable
stability in the gastrointestinal tract, toxicity, bioavailability,
and immunogenicity.
Recently, virus particles have received attention as natural
delivery vehicles for mucosal vaccines and therapeutics
(Eriksson and Holmgren, 2002; Holmgren et al., 2003; Huang
et al., 2005; Takamura et al., 2004). Plant viruses, in principle,
are particularly attractive for these applications because they
are produced in edible hosts. For example, the plant virus5) 224 – 235
www.e
Fig. 1. CPMV particle stability in SGF and SIF. SDS PAGE gel of CPMV
following incubation with SGF for 60 min, SIF for 120 min, or acidic pH for 60
min. The BSA control confirms pepsin (SGF) or pancreatin (SIF) enzyme
activity.
C.S. Rae et al. / Virology 343 (2005) 224–235 225cowpea mosaic virus (CPMV) has been developed as a
nanoparticle platform for vaccine development (Brennan et
al., 1999a; Durrani et al., 1998; Gilleland et al., 2000;
Langeveld et al., 2001; McInerney et al., 1999; Porta et al.,
1994) CPMV, a member of the family Comoviridae, infects the
cowpea plant Vigna unguiculata. The crystal structure of the
CPMV capsid reveals an icosehedral capsid with a 31-nm
diameter consisting of 60 copies each of a large (L) and a small
(S) capsid protein (Lin et al., 1999). CPMV is in the same virus
superfamily as picornaviruses. Notably, these viruses share a
very similar tertiary and quaternary capsid structure where the
picornavirus VP1 is analogous to the CPMV S, and the VP2
and VP3 together are analogous to the CPMV L, suggesting a
common ancestor (Lin et al., 1999). CPMV has been shown to
be stable in a variety of environmental conditions such as low
pH, temperatures up to 60 -C, and organic solvents such as
dimethyl sulfoxide (Wang et al., 2002a). Infection of cowpea
plants typically yields 1 mg of CPMV (approximately 1014
virus particles) per gram of infected leaf tissue (Porta et al.,
1994). The positive-sense bipartite RNA genome of CPMV
consists of RNA-1 (5.9 kb), which codes for the viral protease
and polymerase, and RNA-2 (3.6 kb), which codes for the viral
L and S capsid proteins and the movement protein (Lomonoss-
off and Johnson, 1991). Several sites in the L and S proteins
have been shown to be amenable to the insertion of
heterologous sequences by genetic manipulation of cDNA
clones of RNA-2 (Porta et al., 1994). These properties have
facilitated the development of CPMV for a variety of
applications such as vaccines, antiviral therapeutics, nanoscale
chemical building blocks, and inorganic–organic nanoparticle
hybrids (Brennan et al., 1999b; Durrani et al., 1998; Gilleland
et al., 2000; Khor et al., 2002; McInerney et al., 1999; Raja et
al., 2003a, 2003b; Wang et al., 2002a, 2002b, 2002c).
Despite the wide variety of applications in which CPMV is
under development, and a proven ability of CPMV-based
vaccines to induce mucosal immune responses, the bioavail-
ability of CPMV in vivo via oral or other routes has not been
studied. CPMV particles are approximately 31 nm in diameter
and have a slightly negative surface charge at acidic pH
suggesting that they may be suitable for uptake in the intestinal
epithelium (Vijay Reddy, TSRI, personal communication). The
intestinal epithelium is comprised of several cell types
including epithelial cells and M cells. M cells are specialized
epithelial cells that are responsible for sampling particulate
antigens in the gut, showing a preference for particles that are
between 25 and 100 nm in size, with a neutral to negative
charge. These features, in combination with CPMV nanopar-
ticle stability and an edible host plant suggest that CPMV could
be taken up by the gastrointestinal epithelium, and act as an
oral delivery agent for vaccine or therapeutic applications.
Initially, we needed to determine if the virus would travel
through the gastrointestinal tract intact or be degraded and/or
excreted. We first sought to evaluate the stability of CPMV
under simulated gastric conditions in vitro. Next, we asked if
CPMV could be translocated to tissues in vivo by oral
inoculation, requiring transport across the intestinal epithelia,
or via the circulation by intravenous (i.v.) injection. To evaluatethe trafficking of CPMV particles in vivo, mice were
inoculated with CPMV by oral or intravenous routes and the
localization of CPMV in a variety of tissues was determined by
detecting both the presence of viral capsids and internal viral
RNA. Finally, the stability and infectivity of CPMV particles
following oral delivery was assessed.
Results
Wild-type CPMV retains stability and infectivity under
simulated gastric conditions
It has previously been noted that CPMV capsids are stable at
acid pH and in low concentrations of pepsin (Xu et al., 1996).
We studied whether CPMV would remain stable and infectious
following treatment in simulated gastric fluid (SGF) containing
pepsin at pH 2.0, or in simulated intestinal fluid (SIF)
containing pancreatin at pH 6.8. These in vitro conditions are
typically used in pharmacokinetic or food science studies to
evaluate the stability of proteins or formulations in the
gastrointestinal environment (Takagi et al., 2003). CPMV
(200 Ag) was incubated for varying times between 0 and 60
min in SGF or up to 120 min in SIF followed by removal of
aliquots that were neutralized with bicarbonate. Visualization
of SGF or SIF-treated CPMV on a Coomassie-stained gel
showed that the L and S subunits remained intact throughout
the time course with either treatment (Fig. 1). Pepsin (35 kDa)
is also visible in the samples (Fig. 1, lane 1). As a positive
control, BSA (200 Ag) was treated with SGF and proteolytic
fragments appeared within 60 min of treatment (Fig. 1, Lane
6). To test the effects of simulated gastric conditions on CPMV
infectivity, serial dilutions of CPMV that had been treated with
SGF (60 min) or SIF (120 min) were inoculated onto 7-day-old
cowpea plants. At day 14 post-inoculation, the presence of
lesions per sample of CPMV inoculated was noted. CPMV
treated with SGF or SIF demonstrated infectivity similar to
Fig. 2. RT-PCR detection of CPMV RNA in mouse tissues. (Top) One day following oral gavage with 500 Ag of CPMV per mouse or (bottom) sham-inoculated.
Positive controls: RNA purified from CPMV-infected cowpea leaves.
C.S. Rae et al. / Virology 343 (2005) 224–235226untreated CPMV (not shown). These results indicate that
CPMV is resistant to simulated gastric or intestinal conditions
and suggest that CPMV is likely to remain stable in the
gastrointestinal tract in vivo.
CPMV travels to a variety of tissues in vivo
To study the tissue distribution of CPMV following
different routes of delivery in the mouse, the presence of
CPMV in mouse tissues was first determined by assaying for
the CPMV genomic RNA by RT-PCR. We reasoned that the
single-stranded viral RNA would be protected from degrada-
tion in vivo when packaged inside intact CPMV capsids.
Tissues were isolated from mice following CPMV administra-
tion by intravenous inoculation or by oral gavage. A duplicate
group of inoculated animals underwent cardiac perfusion prior
to tissue dissection to exclude virus that might be present in the
bloodstream. RT-PCR products from a representative CPMV-
inoculated mouse and sham (PBS)-inoculated control mouse
injected i.v. at day 1 post inoculation are shown in Fig. 2.
Although the levels of PCR product in some tissues (e.g. liver)
appear lower in Fig. 2 when comparing band intensity between
samples from animals in each group, no statistically significant
differences were observed. CPMV RNA was detected in all
tissue examined of mice inoculated by i.v. injection in both
perfused and non-perfused groups. Viral RNA persisted in
tissues throughout days 2 and 3 post inoculation in the i.v.
group (Table 1). No CPMV-specific PCR products were
detected in sham-inoculated control mice (Table 1; Fig. 2).
CPMV RNA was not detected in any tissues examined on
either day 5 or day 7 post-inoculation (data not shown).Table 1
Detection of CPMV RNA in tissues of mice inoculated i.v. with CPMV
Tissue Non-perfused Perfused Sham
day 1 day 2 day 3 day 1 day 2 day 3
Spleen 3/3 3/3 3/3 3/3 3/3 3/3 0/3
Kidney 3/3 3/3 3/3 3/3 3/3 3/3 0/3
Liver 2/3 3/3 3/3 3/3 3/3 3/3 0/3
Lung 3/3 3/3 3/3 3/3 3/3 3/3 0/3
Brain 3/3 3/3 3/3 3/3 2/3 3/3 0/3
Bone marrow 3/3 3/3 3/3 3/3 3/3 3/3 0/3
Stomach 3/3 3/3 1/3 3/3 3/3 3/3 0/3
Duodenum 3/3 3/3 2/3 2/3 3/3 3/3 0/3
Jejunum 3/3 3/3 3/3 3/3 3/3 3/3 0/3
Ileum 3/3 3/3 3/3 3/3 3/3 3/3 0/3For mice that received CPMV via the oral route, CPMV
RNA was similarly detected in all tissues examined at day 1
post inoculation in both perfused and non-perfused groups
(Table 2). CPMV RNA persisted in kidney, liver, lung, bone
marrow, and brain in the orally-inoculated group, as well as in
the gastrointestinal tract. Within the gastrointestinal tract, there
was less signal at day 2 and day 3 in perfused animals,
suggesting that in these tissues, much of the virus detected is in
the blood. The presence of CPMV in the blood following oral
gavage was also investigated (not shown). CPMV RNA was
detected in the blood of all orally gavaged mice at 4 h (n = 5), 1
day (n = 5), 2 days (n = 4), and 3 days (n = 5) post-inoculation.
These results indicate that CPMV was systemically distributed
in mice via the vasculature to either bind the endothelium or
enter the tissue parenchyma in a variety of tissues following
oral or i.v. inoculation.
The oral gavage procedure introduces an inoculum directly
into the stomach with a possibility of trauma to the esophagus
or stomach epithelium allowing virus to directly enter the
circulation. To determine if the systemic trafficking of CPMV
observed was a result of the gavage procedure, we allowed
mice to ingest 1 g of CPMV-infected cowpea leaves, which
contained approximately 1 mg of CPMV (1.08  1014 virus
particles). Three mice on day 1 post-ingestion and two mice
each on days 2 and 3 post-ingestion were euthanized and the
same tissues extracted as from the orally-gavaged mice. The
proportion of mice that were positive for CPMV RNA on days
1, 2, and 3 was determined for each tissue (not shown). Similar
to the mice receiving CPMV by oral gavage, on day 1 post-
ingestion, a systemic distribution of CPMV was apparent, with
CPMV RNA being detected in the spleen, liver, lungs,Table 2
Detection of CPMV RNA in tissues of mice inoculated orally with CPMV
Tissue Non-perfused Perfused Sham
day 1 day 2 day 3 day 1 day 2 day 3
Spleen 3/3 1/3 0/3 3/3 0/3 0/3 0/3
Kidney 3/3 0/3 1/3 3/3 3/3 2/3 0/3
Liver 3/3 3/3 2/2 3/3 3/3 3/3 0/3
Lung 3/3 1/3 1/3 3/3 2/3 1/3 0/3
Brain 3/3 1/3 3/3 3/3 1/3 2/3 0/3
Bone marrow 3/3 0/3 1/3 2/3 0/3 0/3 0/3
Stomach 3/3 1/3 3/3 2/3 1/3 0/3 0/3
Duodenum 3/3 1/3 2/3 3/3 1/3 0/2 0/3
Jejunum 3/3 0/3 2/3 3/3 1/3 0/2 0/3
Ileum 3/3 3/3 2/3 3/3 1/3 1/3 0/3
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as in the kidney, duodenum, jejunum and brain in 1 out of 3
mice. These results are consistent with the initial pattern of
tissue distribution of CPMV particles observed following oral
gavage with purified CPMV. The RT-PCR results indicate that
the ability of CPMV to access the systemic circulation
following oral administration is a natural consequence of
eating infected leaves and is not an artifact of the gavage
procedure. In contrast to animals receiving purified CPMV by
gavage, CPMV RNA did not persist in tissues past the first
day following ingestion of infected leaves. This may reflect
differences in the accessibility to the gut epithelial lining of
purified viruses versus viruses possibly bound to other
proteins within infected leaves. Alternatively, there may be
less virus available to reach the circulation when it is
delivered via leaves.
Fluorescent labeling of CPMV to track viruses in vivo
The above experiments measured RNA packaged inside
virus particles as an indication of the presence of CPMV in
tissues. It is possible, however, that free RNA had been
delivered to tissues in the absence of intact particles. To
confirm that particles were being detected, we performed a
complementary study in which the trafficking of CPMV
particles labeled with a fluorescent dye was followed in
mice. The CPMV capsid has five reactive lysine residues on
each asymmetric unit, with one residue on the small subunit,
Lys 38, having the highest reactivity (Chatterji et al., 2004b;Fig. 3. Characterization of Oregon Green-conjugated CPMV (OG-CPMV) particles.
reactive lysines on the asymmetric unit of the CPMV capsid was performed to produce
CPMV) and OG-CPMV were analyzed by size-exclusion chromatography (panels A a
transmission electron microscopy (panels C and D).Wang et al., 2002a). The surface lysine residues have been
successfully conjugated to chemicals such as dye molecules
and proteins (Chatterji et al., 2004a; Wang et al., 2002a,
2002c). After testing several different fluorophores for the
most sensitive detection in the widest variety of tissues, we
used these reactive lysines to conjugate the NHS ester of the
Oregon Green-488 fluorophore onto the CPMV particle.
Dilutions of free OG-488 dye were prepared in phosphate-
buffered saline and the fluorescence emissions were detected
using a fluorescence spectrophotometer (see Materials and
methods). The standard curve of OG-488 dye concentration
versus fluorescence emission intensities was plotted. Each
data point was the average of values obtained from three
independent parallel measurements, with a standard deviation
of 1% between measurements. The fluorescence emission
intensity of OG-488 dye conjugated to a known concentra-
tion of CPMV was measured and the concentration of OG-
488 dye conjugated to CPMV was determined from the
standard curve. Using this method, the dye/particle ratio was
found to be 130 dye molecules per particle for the stock of
OG-CPMV.
The integrity of the fluorescent viruses was monitored by
three different methods: sucrose gradient centrifugation, size
exclusion chromatography, and transmission electron micros-
copy (TEM) (Fig. 3). OG-CPMV demonstrated unique
excitation at 494 nm, confirming that the OG fluorophore
was indeed attached to the CPMV particles (Figs. 3A and B).
In the sucrose gradient, the OG-CPMV virus suspension
separated into distinct bands of intact particles that fluorescedConjugation of the NHS ester of fluorescent dye Oregon Green-488 (OG-488) to
the dye-conjugated Oregon Green-CPMV (OG-CPMV).Wild-type CPMV (WT
nd B, respectively), sucrose gradient sedimentation (insets in panels A and B) and
C.S. Rae et al. / Virology 343 (2005) 224–235228under UV light (Fig. 3B versus the non-fluorescent wild-type
CPMV bands in Fig. 3A). The upper and lower virus bands
separated by sucrose gradient correspond to intact CPMV
middle- and bottom-component particles encapsidating either
RNA-2 or RNA-1, respectively. Intact virions were detected by
size exclusion chromatography on a Superose-6 column with
retention times of approximately 25 min at an elution rate of
0.4 ml/min (Figs. 3A and B). In contrast, broken particles and
individual subunit proteins, which typically elute from the
column after 50–60 min, were not detected in significant
amounts. The intact nature of both wild-type CPMV and OG-
CPMV was confirmed by transmission electron microscopy
(Figs. 3C and D).
Trafficking of OG-CPMV in vivo
To measure the trafficking of OG-CPMV in vivo, mice (3/
group) were injected intravenously with 100 Ag per mouse of
OG-CPMV. At 1, 2, and 3 days post-injection a duplicate set of
animals was perfused, tissues were harvested from both sets
and the OG-specific fluorescent signal measured for each tissue
(Fig. 4). OG-CPMV was detected in the following tissues:
spleen, kidney, liver, lung, stomach, duodenum, jejunum,
ileum, lymph nodes, and brain. Some variation in the presence
and quantity of OG-CPMV was observed. These results
confirm that CPMV enters the tissues from the vascular system
and support the tissue distribution of CPMV following i.v.
administration that was observed by RT-PCR (Table 1). To
determine whether OG-CPMV could be detected in tissuesFig. 4. Systemic trafficking in mice inoculated intravenously with OG-CPMV. OG-C
harvested from three individual mice (black, white and hatched bars, respectively) re
saline-perfused, (E) Day 2 saline-perfused, (F) Day 3 saline-perfused post-inoculatfollowing oral administration, mice (3/group) were adminis-
tered 500 Ag OG-CPMV by oral gavage and one set received
cardiac perfusion with saline at the time of tissue harvest.
Again, OG-CPMV was detected in each tissue but with some
variation among mice (Fig. 5). At days 1 and 2, fluorescence
was detected in most tissues at lower levels than the i.v. groups
but at higher levels at day 3. Although CPMV particles
themselves were stable in the simulated gastrointestinal
environment, an experiment evaluating the stability of OG-
CPMV in SGF showed that there was 20–40% removal of the
dye from the particles after a 60-min incubation (not shown),
indicating that the particle-dye linkage might be exposed on the
particle surface and thus more susceptible to pepsin cleavage
than the rest of the particle. To determine whether free dye
might be contributing to the observed localization in tissues, a
control experiment inoculating animals orally with free dye
was also performed to ask whether dye might be detached from
the particles in the gastrointestinal tract. The fluorescence due
to free OG-488 dye was negligible in all tissues at all time
points with the exception of the gastrointestinal tissues and the
mesenteric and cervical lymph nodes in 1 of 3 mice (not
shown). Together with the PCR results, these data suggest that
the plant virus CPMV enters the mammalian systemic
circulation following oral administration and enters the tissue
parenchyma in a variety of tissues.
The fluorescence measurements provide a useful means
to compare relative amounts of CPMV particles between
tissues of mice in different treatment groups. There was
higher mouse-to-mouse variation in OG-488 fluorescencePMV fluorescence detected (Absorbance Units (A.U.) per mg tissue) in tissues
ceiving OG-CPMV intravenously. (A) Day 1, (B) Day 2, (C) Day 3, (D) Day 1
ion.
Fig. 5. Systemic trafficking in mice inoculated orally with OG-CPMV. OG-CPMV fluorescence detected (A.U. per mg tissue) in tissues harvested from three
individual mice (black, white and hatched bars, respectively) receiving OG-CPMV by oral gavage. (A) Day 1, (B) Day 2, (C) Day 3, (D) Day 1 saline-perfused, (E)
Day 2 saline-perfused, (F) Day 3 saline-perfused post-inoculation.
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than intravenous administration, suggesting that the efficien-
cy of uptake of CPMV in the gastrointestinal tract is
variable in individual mice or that variable amounts of
degradation of the fluorescent dye occurs in the gastroin-
testinal tract, but overall the distribution patterns of CPMV
particles in both i.v.-inoculated and orally-inoculated mice
were similar.
Recovery of CPMV particles from mouse tissues
The results of both the RT-PCR and fluorescence experi-
ments suggested that intact CPMV particles were being
recovered from tissues. To determine whether the recovered
virus particles were infectious to plants, tissue homogenates
from liver and spleen combined from several animals were
PEG-precipitated and inoculated onto cowpea seedlings. Five
to 7 days post-inoculation, RNAwas extracted from the treated
leaves and from secondary leaves, and CPMV-specific RT-PCR
was performed. A control experiment titrating the appearance
of symptoms and RT-PCR products showed that 10 ng of
inoculated CPMV was required to observe symptoms and 1 ng
for a PCR signal, respectively (not shown). No symptoms were
observed on the inoculated primary leaves or on secondary
leaves. While faint RT-PCR bands were detected from primary
leaves, indicating the presence of viral RNA in the inoculum as
previously demonstrated, CPMV-specific PCR products were
not detected in secondary leaves suggesting that replication andspread within the plant did not occur (data not shown). These
experiments were performed several times with similar results.
These data suggest that either the amount of CPMV recovered
from tissues is too low to initiate an infectious cycle in plants,
or that the virus particles that are recovered are somehow
inactivated.
Infectivity of CPMV is reduced following incubation with
murine blood
Since it was demonstrated in vitro that CPMV is resistant to
simulated conditions of the stomach and gastrointestinal tract
(Fig. 1), we hypothesized that the virus is inactivated following
oral or i.v. inoculation by a separate and independent
mechanism in the circulation. To investigate whether compo-
nents of the blood are responsible for inhibition of virus
infectivity, CPMV was incubated with either plasma or serum
for 30 min at 37 -C and inoculated into leaves of 7-day-old
cowpea plants at a concentration 300-fold greater than that
required to produce symptoms. Inoculated plants were ob-
served daily for the appearance of lesions. By day 4 post-
inoculation, a control infection showed severe symptoms on all
primary leaves, while plants inoculated with plasma- or serum-
incubated virus showed almost no signs of infection (Fig. 6).
By day 7, infection was observed in most plants but at distinct
levels of infection among different groups. Plants infected with
plasma-incubated virus produced an average of 6 lesions per
cm2 on primary leaves, while those infected with serum-
Fig. 6. Inactivation of CPMV infectivity by murine serum and plasma. Cowpea leaves inoculated with CPMV that had been incubated with either PBS (A–D),
mouse plasma (E–H), or mouse serum (I–L). Presence of typical mosaic symptoms on leaves was noted at various times post-infection as indicated.
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control infection showed too many lesions to count in all
primary leaves. This experiment suggests that blood compo-
nents found in the plasma and serum significantly inhibit the
infectivity of CPMV in plants.
Discussion
This study demonstrates that the plant virus CPMV shows a
natural bioavailability in mammals. CPMV may be delivered
orally, transported across the intestinal epithelia of mice, and
translocated to a variety of tissues in vivo. The pattern of
CPMV localization in mice was ascertained by two indepen-
dent methods that suggest CPMV particles disseminate
systemically from the gastrointestinal tract via the blood. Virus
particles were present in the systemic circulation as well as the
tissue parenchyma. These results confirm that the biophysical
characteristics of CPMV nanoparticles, including stability at
low pH, size, and resistance to proteolysis, renders them able to
traffic into the systemic circulation from the gastrointestinal
tract.
The general similarity in CPMV distribution patterns
between perfused and non-perfused mice indicates that
CPMV particles are present not only in the vasculature, but
that some particles bind to endothelial cells or enter the tissue
parenchyma as well. Interestingly, we saw this phenomenon
in brain. We noted the presence of CPMV in brain in perfused
animals by the PCR method regardless of the route of
inoculation (Tables 1, 2). Using OG-CPMV however, we
observed CPMV only in the perfused brain following
intravenous administration, suggesting that the specific
fluorescence in the brain endothelium or parenchyma ishigher when the blood is removed (Fig. 4), and that when
introduced by the oral route less virus may reach the brain. It
is possible, however, that a small amount of CPMV gains
access to the brain parenchyma. The picornaviruses poliovirus
and coxsackievirus are able to enter the central nervous
system from peripheral enteric sites by axonal transport and
such access appears to be independent of known virus
receptors (Feuer et al., 2003; Ohka et al., 1998; Yang et al.,
1997). Our results suggest that if neuronal access is occurring
the transport may be a feature of capsid structures in the
picornavirus superfamily and the ability to interact with the
neuronal architecture. Alternatively, it is possible that CPMV
may be present within endothelial cells in the brain.
Preliminary studies in our laboratory suggest that vascular
endothelium internalizes CPMV in vivo (Lewis et al.,
submitted). In addition, preliminary studies in our laboratory
indicate a specific interaction between the CPMV capsid and
mammalian proteins, and this interaction may coat or
inactivate the CPMV capsid so that it is non-infectious for
plants (K. Koudelka and M. Manchester, unpublished data).
Sensitive pharmacokinetic studies using radiolabeled CPMV
particles will be an appropriate way to further quantify the
bioavailability, half-life, and tissue accessibility of CPMV
particles, particularly for the brain, and these studies are in
progress.
One consideration when using a proteinaceous nanoparticle
is the potential for immune responses against the protein coat.
CPMV has been exploited as a nanoparticle platform for
presenting immunogenic epitopes for vaccine development,
thus it is known that the nanoparticle itself can be immuno-
genic (Raja et al., 2003a, 2003b), although immune stimulation
via the oral route is negligible in mice (Brennan et al., 1999a;
C.S. Rae et al. / Virology 343 (2005) 224–235 231Durrani et al., 1998). Preliminary studies by our group
indicate that preexisting humoral immunity to CPMV does
not impede oral trafficking (M. J. Gonzalez and M.
Manchester, unpublished). In addition, we have shown that
it is possible to modulate the anti-CPMV antibody response if
desired by chemically conjugating particles to polyethylene
glycol (PEG) (Raja et al., 2003a, 2003b). Further, recent
studies have indicated that existing anti-nanoparticle
responses do not inhibit the subsequent development of
epitope-specific responses to antigenic peptides on viruses or
virus-like particles (Mandl et al., 2001; Ruedl et al., 2005).
Interestingly, ingestion of black-eyed peas has long been a
preventative practice for measles virus (MeV) infection in
certain parts of Africa, and it has recently been shown that
CPMV and MeV share an antibody epitope (Olszewska and
Steward, 2003). Our studies support the idea that oral delivery
of an immunogen as part of the CPMV nanoparticle is likely
to be a feasible vaccination strategy if sufficient immunity is
induced. Together, these studies provide further evidence for
the feasibility of ‘‘biofarming’’ vaccines by producing viral
nanoparticle-based immunogens in plants (Olszewska and
Steward, 2003).
This use of CPMV nanoparticles represents a novel
strategy for oral delivery of therapeutics. It is not known
how CPMV crosses the intestinal epithelium, however, uptake
of other orally-delivered particulates in the intestine is mainly
focused in the Peyer’s patches (PP) of the small and large
intestine. PP are intestinal protrusions of lymphoid aggregates
or follicles on the anti-mesenteric side of the gut wall and are
covered by a monostratified epithelial layer termed the
follicle-associated epithelium or FAE (Hussain et al., 2001;
Kerneis and Pringault, 1999). Specialized epithelial cells
called M (or membranous) cells are scattered throughout the
FAE and are important in sampling particulate antigens in the
gut lumen and passing them across the epithelium (Gebert et
al., 1996; Neutra et al., 1996, 1999). M cells are capable of
internalizing particulates in a broad size range from 28 nm to
several microns (Beier and Gebert, 1998; Jani et al., 1994;
Neutra et al., 1999; O’Hagan, 1990). PP appear to take up
particles of varying hydrophobicity, but the size and surface
charge of particles seem to be factors in their ability to
passage through the mucus layer overlying the intestinal
epithelia to contact M cells and intestinal enterocytes (Beier
and Gebert, 1998; Hussain et al., 2001). For example, cationic
dyes in the nanometer size range tend to get trapped in the
negatively charged mucus, while negatively charged carbox-
ylated fluorescent latex nanoparticles of similar size have
been shown to permeate the mucus layer. However, strongly
negatively charged particles may be repelled from the mucus
layer and carried away from M cells by mucus flow
(Szentkuti, 1997). Poliovirus with its analogous capsid
structure to CPMV is known to be transcytosed by M cells
in the intestine (Neutra et al., 1996, 1999; Ohka et al., 1998;
Ouzilou et al., 2002). Based on the particle size and
biochemical characteristics, it seems likely that CPMV is
taken up by M-cells in Peyer’s patches and this possibility is
under investigation. Preliminary studies indicate that CPMVco-localizes with M-cells in the epithelium of the mouse
ileum and is deposited in the underlying PP lymphoid tissue
(C. R. and M.J. G., unpublished data).
Our results also suggest that systemic exposure to plant
viruses naturally found in food sources is likely to be a
frequent occurrence. For example, the host plant for CPMV,
Vigna unguiculata or black-eyed bean, is a food source in
parts of Africa and South America and the virus is found in
high concentrations both in the leaves and in the beans
(Olszewska and Steward, 2003). The consequences of
ingestion and systemic exposure to plant viruses are unknown,
but may be a heretofore unrecognized source of antigen
exposure. Although it is a member of the picornavirus
superfamily, the host range of CPMV is restricted to plants
with no evidence that replication of CPMV occurs in mice.
Nevertheless, there are examples of viral host ranges spanning
the plant and animal kingdoms (Dasgupta et al., 2003; Selling
et al., 1990). Our findings that CPMV nanoparticles remain
intact following in vivo administration, combined with their
structural relationship to picornaviruses of mammals, suggest a
possible opportunity for inter-kingdom transmission of
picorna-like viruses from plants to animals on an evolutionary
time scale (Hendrix, 1999). Of course, this raises safety
considerations for working with plant viruses in the laboratory,
and it has been shown that CPMV may be inactivated by UV
irradiation (Langeveld et al., 2001). Importantly, our studies
also show that CPMV is bioavailable when administered in an
edible form in cowpea leaves. A similar distribution of CPMV
RNAwas observed in mice that ingested CPMV in the form of
CPMV-infected leaves as that observed in mice that received
CPMV by oral gavage, except at lower levels. This
discrepancy could be due to fewer CPMV particles being
available from the infected leaves in comparison to purified
virus because the liberation of CPMV particles from the leaves
during chewing and digestion is likely to be less efficient than
mechanical purification. Importantly, the similarity in tissue
distribution between the two routes indicates that the systemic
dissemination of CPMV induced by oral inoculation is due to
particle uptake by the intestinal epithelia and subsequent
passage into the general circulation, and not to entry of virus
particles into the circulation as a result of trauma to the GI
tract by the oral gavage procedure. In addition, the results
suggest that CPMV-based edible therapeutics or vaccines are
feasible and that further purification of viruses from infected
plant tissue may not be necessary. This is especially significant
since CPMV particle stability was demonstrated under
relatively natural conditions of ingestion, in contrast to some
other nanoparticle systems that use more artificial routes of
administration such as direct injection into the intestine or
neutralization of stomach acidity to bypass the degradative and
acidic environment of the stomach, pancreatic lipases, and bile
digestive enzymes of the duodenum (Damge et al., 2000;
Wells et al., 1998). This makes it possible to generate edible
vaccines or therapeutics for use in developing countries.
Finally, the favorable in vivo characteristics of CPMV
nanoparticles support their further development for applica-
tions such as drug delivery.
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Preparation of purified cowpea mosaic virus (CPMV)
cDNA clones of the CPMV genome were used to infect
Kentucky cowpea (Vigna unguiculata) plants (Dessens and
Lomonossoff, 1993) following which CPMV was purified
from infected leaves by a method previously described (Khor et
al., 2002). The purification of intact CPMV particles was
confirmed by analysis on an AKTA Explorer Superosei-6
size-exclusion column (Amersham Pharmacia). Virus samples
suspended in 0.1 M phosphate buffer (pH 7.0) were applied to
the column and following a wash with phosphate buffer,
CPMV particles were eluted at a rate of 0.4 ml/min. TEM
analyses were performed by depositing 20 Al aliquots of each
sample onto 100-mesh carbon-coated copper grids for 2 min.
The grids were then stained with 20 Al of 2% uranyl acetate and
viewed with a Philips CM100 electron microscope.
Stability of CPMV particles in simulated gastric conditions
Simulated gastric fluid (SGF) and simulated intestinal fluid
(SIF) were prepared according to Takagi et al. (2003). Briefly,
pepsin (3.8 mg; Sigma) was dissolved into 5 ml of gastric
control fluid (2 mg/ml NaCl, pH 2.0). SIF was prepared by
dissolving pancreatin, (10 mg/ml; Sigma) in intestinal control
fluid (0.05 M KH2SO4, pH 6.8). Both solutions were used
within the same day. SGF (400 Al) was first incubated at 37 -C
for 2 min before addition of CPMV (200 Ag), giving a ratio of
10 U of pepsin activity/Ag of CPMV. The tube contents were
mixed by mild vortexing and the tube was immediately placed
in a 37 -C water bath for time points ranging from 0 to 60 min,
followed by neutralization with 70 Al of 200 mM sodium
bicarbonate solution. Similarly, SIF was incubated at 37 -C for
2 min before addition of CPMV (200 Ag) and the tube contents
were placed in a 37 -C water bath for time points up to 120 min.
Aliquots of virus exposed to SGF or SIF were mixed with 5 Al of
NuPAGE 4 LDS-sample buffer, run on 4–12% SDS-PAGE
gels, and stained with Simply Blue Safe Stain (Invitrogen).
Aliquots of SGF- or SIF-treated virus containing serial 10-fold
dilutions of CPMV ranging from 12.5 Ag to 0.125 ng were also
inoculated onto primary leaves of 7-day-old cowpea seedlings
that had been dusted with carborundum. Five to 7 days later, the
leaves were observed for the presence of mosaic lesions.
Animals
All animals used in this study were 6–8 week old female
C57 BL/6 mice obtained from The Scripps Research Institute
Rodent Breeding Colony. Animals were used in compliance
with IACUC approved protocols.
Isolation of RNA from mouse tissues following CPMV
inoculation
Forty mice were inoculated with CPMV either by oral
gavage or intravenous (i.v.) injection. Four groups of ten miceeach were obtained and designated as follows: (1) Nine mice
received 500 Ag CPMV (5.37  1013 virus particles) each in
250 Al sterile, endotoxin-free PBS and one control sham-
inoculated mouse received 250 Al sterile, endotoxin-free PBS
by oral gavage. (2) Nine mice received 500 Ag CPMV (5.37 
1013 virus particles) each in 250 Al sterile, endotoxin-free PBS
and one control sham-inoculated mouse received 250 Al sterile,
endotoxin-free PBS by oral gavage. In addition, all were
cardiac perfused at the time of sacrifice with sterile PBS after
anesthetization with an intraperitoneal injection of chloral
hydrate. (3) Nine mice received 100 Ag CPMV (1.08  1013
virus particles) in 200 Al sterile, endotoxin-free PBS, and one
control sham-inoculated mouse received 200 Al sterile, endo-
toxin-free PBS by intravenous injection. (4) Nine mice
received 100 Ag CPMV (1.08  1013 virus particles) in 200
Al sterile, endotoxin-free PBS and one control sham-inoculated
mouse received 200 Al sterile, endotoxin-free PBS by
intravenous injection. In addition, all were cardiac perfused
at the time of sacrifice with sterile PBS after anesthetization
with an intraperitoneal injection of chloral hydrate. On day one
post-inoculation, four mice per group including one sham-
inoculated control, were either perfused or sacrificed by
halothane depending on the designated group and portions of
each of the following tissues were harvested, snap-frozen in
liquid nitrogen, and stored at 80 -C for later RT-PCR
analysis: spleen, kidney, liver, lung, stomach, duodenum,
jejunum, ileum, brain, and bone marrow. Three mice per each
perfused and non-perfused group were euthanized on day 2 and
day 3 post-inoculation and the same tissues were collected and
similarly stored for later RT-PCR analysis.
To examine the trafficking of CPMV using ingested,
infected leaves, another group of seven mice was deprived of
solid food for 1 day and each mouse was placed in a separate
cage containing 1 g of CPMV-infected leaves (5 leaves)
containing approximately 1 mg of CPMV (1.08  1014 CPMV
particles). Each mouse ingested the entire gram of infected
leaves within a day. Three mice were euthanized on day 1 post
inoculation and two mice per day on days 2 and 3 post
inoculation; tissues were isolated for RT-PCR as described
above.
RT-PCR
Tissues isolated from mice were homogenized with a hand-
held homogenizer (Omni International, Warrenton, VA) in TRI
reagent (MRC Inc, Cincinnati, OH) and RNA was then
extracted according to the manufacturer’s instructions. Follow-
ing this, cDNA was synthesized using MMLV-RT and the
downstream CPMV RNA 2 primer ßBßCREV (5V CGTATTC-
CAATTGTCATCACC 3V). The ßBßCREV primer (60 pmol)
was mixed with 500 ng of each tissue RNA and heated to
70 -C for 5 min, following which 20 units of RNAsin
(Promega, Madison, WI, USA), 4 mM each of dATP, dTTP,
dCTP, and dGTP (Roche, Mannheim, Germany), 20 units of
MMLV-RT (Promega, Madison, WI) and MMLV-RT buffer
were added. cDNA synthesis was carried out at 37 -C for 1.5 h
followed by a 10-min incubation at 70 -C to inactivate the
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Al reaction mix consisting of 5 Al of cDNA, 8 nmol each of
dATP, dTTP, dCTP, and dGTP (Roche, Mannheim, Germany),
60 pmol each of the upstream primer ßBßCFOR (5V
GCACAAGGACCTGTTTGTGC 3V) and downstream primer
ßBßCREV (described above), 0.5 units of Taq polymerase
(Roche, Mannheim, Germany), Taq polymerase buffer contain-
ing Mg (1.5 mM) supplied by the manufacturer, and purified
water from Ambion (Austin, TX). Thirty cycles consisting of 1
min denaturation at 95 -C, 1 min annealing at 55 -C, and 1 min
extension at 72 -C were performed, resulting in a 150 bp PCR
product. Five hundred ng of RNA extracted from CPMV-
infected leaves, and purified water (Ambion), were used as
positive and negative controls respectively for the RT-PCR
reactions. All cDNA synthesis and PCR reactions were carried
out in an MJ Research DNA Engine. The PCR products were
analyzed on a 2% Seakem LE (BMA, Rockland, ME) agarose
gel alongside a 1-kb PLUS ladder (Invitrogen, San Diego, CA),
and visualized with ethidium bromide on an AlphaImager 2200
MultiImage Light Cabinet (Alpha Innotech, San Leandro, CA).
Relative intensity of bands on the gels were also quantified
compared to control by spot densitometry (Alpha-Ease FC,
Alpha Innotech). The sensitivity of the RT-PCR protocol was
determined by setting up RT-PCR reactions with amounts of
template CPMV RNA (purified from CPMV-infected cowpea
leaves) ranging from 100 to 1014 copies in increments of
powers of 10. Employing the RT-PCR protocol described, it
was possible to detect 10 copies of CPMV RNA purified from
infected leaves.
Preparation and characterization of fluorescently conjugated
CPMV
Oregon Green 488 (OG-488) carboxylic acid, succinimidyl
ester fluorescent dye (Molecular Probes, Eugene, Oregon) was
conjugated to CPMV by mixing 22.9 mg of wild-type CPMV
with OG-488 (200-fold excess relative to viral asymmetric
subunit) in 11.5 ml of 0.1 M potassium phosphate buffer, pH
7.0, with gentle agitation at room temperature for 24 h. Initial
separation of virus from unconjugated dye was accomplished
by ultracentrifugation at 42,000 rpm over 3 ml of a 30%
sucrose cushion. The pellet was then resuspended in 0.1 M
potassium phosphate and loaded on a 10–40% sucrose
gradient for ultracentrifugation at 28,000 rpm for 3 h. The
extracted bands were further purified by ultracentrifugation at
42,000 rpm for 3 h and the dye-labeled CPMV pellet was
dissolved in 1 ml of sterile PBS (pH 7.0).
Inoculation of mice with Oregon Green 488-conjugated CPMV
(OG-CPMV)
For the determination of CPMV localization by fluorescence
measurements, the same four groups of mice as described
earlier were inoculated with OG-CPMV by either oral gavage
with 500 Ag OG-CPMV (5.37  1013 virus particles) each in
250 Al sterile, endotoxin-free PBS or i.v. injection with 100 Ag
OG-CPMV (1.08  1013 virus particles) in 200 Al sterile,endotoxin-free PBS and were either sacrificed by cardiac
perfusion or euthanized by halothane depending on designated
group. Four mice from each perfused or non-perfused group
including one sham-inoculated control were sacrificed 1 day
post inoculation and the following tissues were extracted, snap
frozen in liquid nitrogen, weighed, and stored at 20 -C for
later fluorescence analysis: spleen, kidney, liver, lung, stomach,
duodenum, jejunum, ileum, lymph nodes, and brain. Tissues
from three mice per group on day 2 and day 3 post-inoculation
were similarly harvested, weighed and stored.
Inoculation of mice with free Oregon Green 488 dye
Mice were administered 3.81 Ag per mouse of free OG-488
dye by oral gavage, the equivalent amount of dye as that
attached to the CPMV particles given by oral gavage. One
mouse per day for 3 days post inoculation was perfused and
tissues were isolated for fluorescence measurements. Similarly,
by the intravenous route three mice were injected with 0.509
Ag per mouse of free OG-488 dye, the equivalent amount of
dye as that attached to the CPMV particles administered i.v.
Tissues were harvested from mice following perfusion as
described above.
Fluorescence measurements
Tissues were isolated and homogenized in PBS, then
centrifuged at 10,000  g for 10 min at 4 -C to precipitate
the cell debris. The OG-488-specific fluorescence emissions in
the clarified tissue supernatants were determined using a Varian
Cary Eclipse fluorescence spectrophotometer. A control sample
of sham-inoculated tissue supernatant from each tissue was
spiked with a known amount of OG-CPMV and the tissue-
specific dye excitation and emission were determined for each
tissue. The determined tissue specific emission k value was
then used in five separate scans of each tissue supernatant
sample, following which the spectra were averaged and the
emission value of the sham-inoculated control sample was
subtracted as background.
Recovery of virus particles from mouse tissues
Four mice were orally inoculated with 150 Ag/mouse of
CPMV and 24 h later, the mice were euthanized and the liver,
spleen, and kidney tissues were extracted and pooled.
Following homogenization of pooled tissue samples in PBS,
the homogenates were centrifuged at 10,000  g for 10 min at
4 -C, and the cleared tissue supernatants were removed to flat-
bottom 50-ml centrifuge tubes, each containing a magnetic
flea. Polyethylene glycol 8000 was added to each supernatant
to a final concentration of 8% and the mixture was stirred for
30 min at 4 -C to precipitate any virus present. The resulting
cloudy mixture was centrifuged at 6000 rpm in a Sorvall RC5C
centrifuge for 15 min and the pellet was resuspended in 50–
500 Al of 0.1 M phosphate buffer (pH 7.0), depending on pellet
size. For each tissue homogenate a 7-day-old cowpea plant was
dusted with carborundum and the resuspended pellet from each
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later, the primary and secondary leaves were harvested and a
circle of tissue weighing 70 mg was excised from each leaf.
RNA was extracted using a Qiagen RNeasy Plant Mini Kit
(Qiagen Research, Maryland, USA) and RT-PCR was con-
ducted as described above. PCR products were electrophoresed
on a 2% Seakem LE agarose gel. The PCR products were
purified from the gel using a PCR purification kit (Qiagen) and
sequenced (Retrogen) to confirm that they were CPMV
specific. Southern hybridization of the products with a
CPMV-specific probe was also performed using 32P end-
labeled oligonucleotides (Amersham Biosciences). PCR pro-
ducts were transferred to Hybond-N+membrane (Amersham
Biosciences) using standard techniques. Hybridization condi-
tions were 3 h at 55 -C and wash conditions were in 6 SSC/
0.5% SDS and were performed twice for 5 min at room
temperature and twice for 5 min at 50 -C.
Infectivity of CPMV following incubation with blood
Whole blood samples were obtained from mice following
cardiac puncture either with or without heparin. Samples were
incubated at 4 -C overnight and then spun at 15,000 rpm for 10
min. Blood plasma or serum were recovered and incubated
with CPMV (15 Ag) in a one to one (v/v) ratio at 37 -C for 30
min while a control CPMV sample was incubated with PBS.
Primary leaves from 7-day-old cowpea plants were then
bruised with carborundum and inoculated with samples (at a
concentration of 3 Ag CPMV per leaf, or 300-fold more virus
than is required to produce lesions) and observed daily for
infection-induced mosaic symptoms.
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